Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Proc Natl Acad Sci U S A ; 115(22): 5744-5749, 2018 05 29.
Article in English | MEDLINE | ID: mdl-29760101

ABSTRACT

The allosteric interplay between distant functional sites present in a single protein provides for one of the most important regulatory mechanisms in biological systems. While the design of ligand-binding sites into proteins remains challenging, this holds even truer for the coupling of a newly engineered binding site to an allosteric mechanism that regulates the ligand affinity. Here it is shown how computational design algorithms enabled the introduction of doxycycline- and doxorubicin-binding sites into the serine proteinase inhibitor (serpin) family member α1-antichymotrypsin. Further engineering allowed exploitation of the proteinase-triggered serpin-typical S-to-R transition to modulate the ligand affinities. These design variants follow strategies observed in naturally occurring plasma globulins that allow for the targeted delivery of hormones in the blood. By analogy, we propose that the variants described in the present study could be further developed to allow for the delivery of the antibiotic doxycycline and the anticancer compound doxorubicin to tissues/locations that express specific proteinases, such as bacterial infection sites or tumor cells secreting matrix metalloproteinases.


Subject(s)
Doxorubicin/metabolism , Doxycycline/metabolism , Protein Engineering/methods , Recombinant Proteins , Allosteric Site/genetics , Doxorubicin/chemistry , Doxycycline/chemistry , Drug Carriers/chemistry , Drug Carriers/metabolism , Humans , Models, Molecular , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , alpha 1-Antichymotrypsin/chemistry , alpha 1-Antichymotrypsin/genetics , alpha 1-Antichymotrypsin/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...